JP
BCRX icon

John Paulson’s BioCryst Pharmaceuticals BCRX Stock Holding History

John Paulson’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-349,500
Closed -$1.94M – 58
2017
Q2 		$1.94M Buy
+349,500
New +$2.13M 0.03% 92
2017
Q1 		– Sell
-52,600
Closed -$366K – 100
2016
Q4 		$333K Sell
52,600
-310,500
-86% -$1.62M ﹤0.01% 97
2016
Q3 		$1.6M Buy
363,100
+100,000
+38% +$399K 0.02% 87
2016
Q2 		$747K Hold
263,100
– – 0.01% 81
2016
Q1 		$745K Buy
+263,100
New +$1.17M 0.01% 91

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

John Paulson's BCRX Position: Q3 2017 in Review

John Paulson sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2017, closing a stake of 349,500 shares — an estimated $1.94M sold.

John Paulson first reported a position in BCRX in Q1 2016 and held it in 5 quarters. The position peaked at $1.94M in Q2 2017. 120 funds tracked by Wall St. Rank hold BCRX as of Q3 2017.

  • John Paulson reported no remaining BioCryst Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • John Paulson sold 349,500 BioCryst Pharmaceuticals shares in Q3 2017, an estimated $1.94M.
  • John Paulson first reported a position in BioCryst Pharmaceuticals in Q1 2016 and held it in 5 quarters.
  • John Paulson's BioCryst Pharmaceuticals position peaked at $1.94M in Q2 2017.
  • 120 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2017.

Based on Paulson & Co's 13F filing for Q3 2017, filed 14 Nov 2017.